K31.A15
Gastric intestinal metaplasia without dysplasia, involving multiple sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Gastric intestinal metaplasia without dysplasia, classified under ICD-10 code K31.A15, is a condition where normal stomach lining cells are replaced with intestinal-type cells across multiple sites in the stomach. While this condition is considered precancerous, it often remains stable for years, though it can increase the risk of developing gastric cancer if it progresses. Recognizing and understanding this condition helps in monitoring and managing stomach health effectively.
Causes & Symptoms
Clinical Causes: Chronic Helicobacter pylori infection Long-standing gastric inflammation or gastritis Lifestyle factors such as heavy alcohol consumption and smoking Diet high in smoked, salted, or poorly preserved foods Genetic predisposition to gastric mucosal changes Environmental factors contributing to chronic gastritis
Key Symptoms: Indigestion or persistent discomfort in the upper abdomen Bloating and feeling full after small meals Nausea or occasional vomiting Unintentional weight loss in some cases Loss of appetite Occasional anemia if bleeding occurs
Diagnostic & Treatment
Diagnosis Path: Diagnosing gastric intestinal metaplasia involves a combination of clinical evaluation and diagnostic procedures, including: - **Endoscopy**: A procedure where a flexible tube with a camera is inserted into the stomach to visualize and obtain tissue samples. - **Biopsy**: Tissue samples are examined under a microscope to identify intestinal metaplasia. - **Histopathologic analysis**: Confirming the presence and extent of metaplasia. - Additional tests may include tests for Helicobacter pylori infection, which is associated with the condition.
Treatment Protocols: Management focuses on monitoring the condition to prevent progression to gastric cancer. Common approaches include: - **Eradication of H. pylori**: Antibiotics and medications to eliminate the infection if present. - **Lifestyle modifications**: Reducing intake of irritants like alcohol, smoked foods, and smoking. - **Regular surveillance endoscopy**: Monitoring for any signs of dysplasia or progression. - **Medication**: Use of proton pump inhibitors (PPIs) to reduce stomach acid and inflammation. - Currently, there are no specific medications to reverse intestinal metaplasia, emphasizing the importance of ongoing clinical monitoring and lifestyle management.
Clinical Advice & FAQs
Billing Guidance
Is K31.A15 a billable ICD-10 code?
Yes, K31.A15 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report K31.A15?
Clinical documentation must specify the nature of Gastric intestinal metaplasia without dysplasia, involving multiple sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference